Ashland, a company that specialises in enabling the use of slow release medicines, has completed a major expansion of its Mullingar campus.
As drug companies looks at new delivery systems to allow patients with chronic conditions to receive their injections less often, demand for bioresorbable polymers is rising. The product can also be used to more finely target sometimes highly toxic medicines for conditions like cancer, reducing the harmful side effects on patients.
According to the most recently filed accounts for Ashland Specialties Ireland Limited, formerly Vornia – the Mullingar-based company acquired by Ashland back in 2017 – the average number of employees on site in the year to September 2023 was 16. That number is expected to rise to around 40 following this investment.
Bioresorbable polymers can also be used to reduce the metal required in medical devices and implants and in the use of dermal fillers and other regenerative medical products.